G. Hamet

Long‐term outcome of primary non‐responders to tenofovir therapy in HIV/HBV‐co‐infected patients: impact of HBV genotype G

P. Marcellin, G. Peytavin, B. Roquebert, 2012, Liver international : official journal of the International Association for the Study of the Liver.

Efficacy and safety of efavirenz, raltegravir and dolutegravir in HIV-1/TB co-infection. A multicenter retrospective cohort study in France.

Y. Yazdanpanah, F. Mechaï, J. Molina, 2022, Journal of acquired immune deficiency syndromes.

Persistent low-level HIV-1 RNA between 20 and 50 copies/mL in antiretroviral-treated patients: associated factors and virological outcome.

C. Charpentier, F. Brun-Vézinet, D. Descamps, 2012, The Journal of antimicrobial chemotherapy.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Management of accidental exposure to HIV: the COREVIH 2011 activity report.

E. Rouveix, E. Bouvet, G. Pellissier, 2014, Medecine et maladies infectieuses.

Safety and efficacy of switching to elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate in treatment-experienced people with HIV: a multicenter cohort study

C. Delaugerre, W. Rozenbaum, F. Mechaï, 2023, AIDS Research and Therapy.

Mortality of people living with HIV in Paris Area from 2011 to 2015.

W. Rozenbaum, J. Molina, P. Sellier, 2020, AIDS research and human retroviruses.

Does region of origin influence the timing and outcome of first‐line antiretroviral therapy in France?

W. Rozenbaum, S. Diamantis, J. Molina, 2018, HIV Medicine.